Khalil Choucair, Chief Fellow of Hematology & Oncology at Karmanos Cancer Institute, reshared a post by BMJ Oncology on LinkedIn, adding:
“Our work exploring potential biomarkers of IO-therapy in patients of extremes of age, is now published in BMJ Oncology.”
Quoting BMJ Oncology‘s post:
“Participation of older patients in immune checkpoint inhibitors trials has been suboptimal, particularly at the extremes of age.”
Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma.
Authors: Khalil Choucair, et al.
